Oppenheimer upgrades Relay Therapeutics (RLAY) to Outperform, citing the strength of its mutant-selective inhibitor pipeline and upcoming catalysts in the breast cancer treatment arena.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
As cargo theft evolves from petty crime to sophisticated, high-value scams, logistics firms like Echo Global Logistics are deploying advanced AI and human vigilance in a high-stakes battle for security. Senior VP Jeff Starr details the new frontline in freight fraud.
A high-earning Orlando software engineer faces a stark choice: pursue a lifelong dream in federal law enforcement at a major pay cut and a significant real estate loss, or stay put in a lucrative tech career. His story highlights the personal costs behind shifting housing markets and career pivots.
Expedia Group stock rose sharply after announcing an expanded, exclusive partnership with Affirm, making the fintech firm the sole 'Buy Now, Pay Later' provider across its major U.S. travel platforms.
Franklin Templeton has launched the Templeton Emerging Markets Debt ETF (TEMD), aiming to give investors targeted exposure to both hard and local currency debt from developing economies, capitalizing on the asset class's recent strong performance.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
London's blue-chip index surged to a historic high as investors rotated into defensive sectors, shrugging off a brutal sell-off in precious metals and oil triggered by geopolitical shifts and regulatory moves.
Sugar futures extended their sharp decline this week, with London white sugar hitting a five-year low, as robust harvests from Brazil and India signal a prolonged period of ample global supplies.
A new study reveals the cost gap between Waymo's driverless vehicles and human-driven Uber and Lyft rides is shrinking, signaling a pivotal moment for the competitive robotaxi industry.
A new Deloitte report urges enterprises to embed accountability and oversight from the start, arguing that governance is not a barrier but an accelerator for scaling autonomous AI systems.
Former Congressman Colin Allred delivers a pointed public rebuke of Texas House member James Talarico, alleging derogatory comments were made during the heated Democratic Senate primary campaign.
After a sharp January sell-off, Shopify's stock is hovering near a significant long-term trendline—a level that has preceded notable rallies in the past.
CNBC's Jim Cramer reaffirmed his bullish stance on Rio Tinto, highlighting the mining giant's role as a strategic hedge against geopolitical and economic volatility during the show's Lightning Round.
CNBC's Jim Cramer reaffirmed his bullish stance on Palantir Technologies during a recent 'Mad Money' segment, placing the data analytics firm in the same league as established giants like ServiceNow and Salesforce.
CNBC's Jim Cramer concedes he misjudged the explosive demand for Apple's iPhone 17, which powered the tech giant to a staggering earnings beat that caught Wall Street off guard.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
